Clinical benefit of preserving residual renal function in dialysis patients: An update for clinicians

American Journal of the Medical Sciences

Volumn 339, Issue 5, 2010, Pages 453-456

  Brener, Zachary Z ^f   Kotanko, Peter ^a,b   Thijssen, Stephan ^b   Winchester, James F ^a,c   Bergman, Michael ^d,e  

^a YESHIVA UNIVERSITY   (United States)

^b RENAL RESEARCH INSTITUTE   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e RABIN MEDICAL CENTER   (Israel)

^f NONE

Author keywords

Hemodialysis; Mortality; Peritoneal dialysis; Residual renal function

Indexed keywords

AMINOGLYCOSIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

CALCIFICATION; ENERGY METABOLISM; FLUID BALANCE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FUNCTION; METABOLIC REGULATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEAL DIALYSIS; PROTEIN METABOLISM; QUALITY OF LIFE; REVIEW;

EID: 77952263320     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181cf7d5b     Document Type: Review

References (46)

1. Termorshuizen F, Korevaar JC, Dekker FW, et al. NECOSAD Study Group: the relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003;41:1293-302.
2. Morduchowicz G, Winkler J, Zabludowski JR, et al. Effects of residual renal function in hemodialysis patients. Int Urol Nephrol 1994;26:125-31.
3. Wang AY, Woo J, Wang M, et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005;20:396-403.
4. Wang AY, Sea MM, Ip R, et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001;12:2450-7.
5. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-8.
6. Wang AY, Wang M, Woo J, et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002;62:639-47.
7. Wang AY, Wang M, Woo J, et al. Inflammation, residual renal function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004;15:2186-94.
8. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-62.
9. Shemin D, Bostom AG, Lambert C, et al. Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition. Perit Dial Int 2000;20:439-44.
10. Shemin D, Bostom AG, Laliberty P, et al. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001;38:85-90.
11. Maiorca R, Brunori G, Zubani R, et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 1995;10:2295-305.
12. Termorshuizen F, Dekker FW, van Manen JG, et al; NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004;15:1061-70.
13. Ates K, Nergizoglu G, Keven K, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001;60:767-76.
14. Konings CJ, Kooman JP, Schonck M, et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 2003;18:797-803.
15. Fagugli RM, Pasini P, Quintaliani G, et al. Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transplant 2003;18:2332-8.
16. McCarthy JT, Williams AW, Johnson WJ. Serum beta 2-microglobulin concentration in dialysis patients: importance of intrinsic renal function. J Lab Clin Med 1994;123:495-505.
17. Montenegro J, Martinez I, Saracho R, et al. Beta 2 microglobulin in CAPD. Adv Perit Dial 1992;8:369-72.
18. Amici G, Virga G, Da Rin G, et al. Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis. Nephron 1993;65:469-71.
19. Copley JB, Lindberg JS. Nontransplant therapy for dialysis-related amyloidosis. Semin Dial 2001;14:94-8.
20. Altmann P, Butter KC, Plowman D, et al. Residual renal function in hemodialysis patients may protect against hyperaluminemia. Kidney Int 1987;32:710-3.
21. Yavuz A, Ersoy FF, Passadakis PS, et al. Phosphorus control in peritoneal dialysis patients. Kidney Int Suppl 2008; 108: S152-8.
22. Wang AY, Woo J, Sea MM, et al. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual renal function: what are the implications? Am J Kidney Dis 2004;43:712-20.
23. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium X phosphate product wit mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
24. Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int 2006;69:1726-32.
25. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001;59:407-14.
26. Wang AY, Lam CW, Wang M, et al. Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis 2005;45:715-29.
27. Witko-Sarsat V, Descamps-Latscha B. Advanced oxidation protein products: novel uraemic toxins and proinflammatory mediators in chronic renal failure? Nephrol Dial Transplant 1997;12:1310-2.
28. Shin SK, Noh H, Kang SW, et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999;19:138-42.
29. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int 1996;50:343-57.
30. Gotch F, Sargent J. A mechanistic analysis of the National Cooperative Dialysis study (NCDS). Kidney Int 1985;28:526-34.
31. Bergstrom J, Lindholm B. Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? Kidney Int Suppl 1993;43:39-50.
32. Wang AY, Sea MM, Ho ZS, et al. Evaluation of handgrip strength as a nutritional marker and prognostic indicator in peritoneal dialysis patients. Am J Clin Nutr 2005;81:79-86.
33. Brener ZZ, Thijssen S, Kotanko P, et al. The impact of residual renal function on infectious outcomes in incident hemodialysis patients. J Am Soc Nephrol 2008;18:291A.
34. Kaysen GA, Dubin JA, Muller HG, et al. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000;58:346-52.
35. Levey AJ. Measurement of renal function in chronic renal disease. Kidney Int 1990;38:167-84.
36. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000;11:556-64.
37. Rottembourg J, Issad B, Gallego JL, et al. Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1983;19:397-403.
38. Misra M, Vonesh E, Van Stone JC, et al. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 2001;59:754-63.
39. Gunal AI, Duman S, Ozkahya M, et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001;37:588-93.
40. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002;17:1814-8.
41. van Olden RW, Guchelaar HJ, Struijk DG, et al. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int 2003;23:339-47.
42. Baker RJ, Senior H, Clemenger M, et al. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003;41:670-5.
43. Weisbord SD, Bernardini J, Mor MK, et al. The effect of coronary angiography on residual renal function in patients on peritoneal dialysis. Clin Cardiol 2006;29:494-7.
44. Dittrich E, Puttinger H, Schillinger M, et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients-a prospective study. Nephrol Dial Transplant 2006;21:1334-9.
45. Tepel M, van der GM, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
46. Li PK, Chow KM, Wong TY, et al. Effects of an angiotensinconverting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003;139:105-12.